Table 1.
Clinical and laboratory characteristics of patients with MCL at diagnosis
| Variable | All patients (n = 92) | De novo MCL (n = 65) | Secondary MCL (n = 27) |
|---|---|---|---|
| Age at MCL diagnosis (y), median (range) | 60.4 (25.4-90.8) | 60.4 (27.1-90.8) | 60.0 (25.4-73.4) |
| Males, n (%) | 59 (64.1) | 43 (66.2) | 16 (59.3) |
| Diagnosis, n (%) | |||
| MCL | 61 (66.3) | 46 (70.7) | 15 (55.6) |
| MCL-AHN | 31 (33.7) | 19 (29.2) | 12 (44.4) |
| MDS/MPN-U | 14 (45.2) | 12 (18.5) | 2 (7.4) |
| CMML | 8 (25.8) | 2 (3.1) | 6 (22.2) |
| CEL/eosinophilia | 3 (9.7) | 2 (3.1) | 1 (3.7) |
| AML | 3 (9.7) | 1 (1.5) | 2 (7.4) |
| Multiple myeloma | 1 (3.2) | 1 (1.5) | 0 |
| NHL | 1 (3.2) | 1 (1.5) | 0 |
| Not specified | 1 (3.2) | 0 | 1 (3.7) |
| C-findings, n/N (%)∗ | |||
| No C-findings present | 13 (14) | 8 (12.3) | 5 (18.5) |
| Hemoglobin < 10 g/dL | 43 (46.7) | 31 (47.7) | 12 (44.4) |
| Platelets < 100 × 109/L | 46 (50.0) | 30 (46.2) | 16 (59.3) |
| Absolute neutrophil count < 1 × 109/L | 2 (2.2) | 2 (3.1) | 0 |
| Weight loss (> 10% in 6 mo) | 41/85 (41.8) | 37/61 (60.7) | 4/24 (16.7) |
| Albumin < 3.5 g/dL | 26/83 (31.3) | 21/57 (36.8) | 5/26 (19.2) |
| Hepatomegaly with ascites or portal hypertension | 19/84 (22.6) | 13/59 (22.0) | 6/25 (24.0) |
| Alkaline phosphatase > 150 U/L | 47/87 (54.0) | 31/60 (51.7) | 16/27 (59.3) |
| Osteolytic lesion(s) ≥ 2 cm | 4/70 (5.7) | 2/51 (3.9) | 2/19 (10.5) |
| Other relevant findings, n/N (%)∗ | |||
| Serum tryptase, μg/L median (range) | 333.5 (50.9-7490) | 308 (57.2-7490) | 396 (50.9-1820) |
| ≥200 μg/L, n (%) | 75 (81.5) | 53 (81.5) | 22 (81.5) |
| Any PB MCs detectable, n/N (%) | 11/89 (12.4) | 8/63 (12.7) | 3/26 (11.5) |
| ≥3% PB MCs | 7/89 (7.9) | 6/63 (9.5) | 1/26 (3.8) |
| ≥10% PB MCs | 4/89 (4.5) | 4/63 (6.3) | 0/26 (0) |
| MC infiltration in BM aspirate smear, %; median (range)† | 30 (20-100) | 30 (20-100) | 30 (20-88) |
| Abnormal karyotype, n/N (%) | 10/60 (17) | 7/38 (18.4) | 3/22 (13.6) |
| S/A/R mutations present, n/N (%) | 16/36 (44) | 9/24 (37.5) | 7/12 (58.3) |
CEL, chronic eosinophilic leukemia; CMML, chronic myelomonocytic leukemia; MDS/MPN-U, myelodysplastic syndrome/myeloproliferative neoplasm-unclassifiable; NHL, non-Hodgkin lymphoma.
∗
Denominator is the total number of patients (92, 65, or 27 for full cohort, de novo, or secondary MCL, respectively) unless otherwise specified.
†
One patient did not have a BM biopsy but had >10% MCs in the PB.